Chronic medication use may increase in breast cancer survivors after cancer treatment
the ONA take:
Researchers report an increase in breast cancer survivor’s use of chronic medication after cancer treatment. The study was published online ahead of print in the journal Supportive Care in Cancer.
For the study, researchers sought to characterize the patterns of medication use by survivors of early-stage breast cancer from diagnosis to 1 year after chemotherapy.
Researchers enrolled 107 patients diagnosed between December 2011 and June 2014, all participants were treated at a single center. Medication use data was retrieved from prescription databases and records from the National Electronic Health Records.
Results showed that 46.7% of participants developed non-cancer comorbidities, including hypertension, hyperlipidemia, and diabetes.
The most common chronic medication types before chemotherapy were calcium channel blockers and lipid-modifying agents. Their use persisted during and after chemotherapy. The most commonly used post-chemotherapy medication was hormonal therapy.
Researchers found that there was a statistically significant increase in the average number of chronic disease medication classes prescribed to patients between the pre-chemotherapy and chemotherapy periods, as well as between the chemotherapy and post-chemotherapy periods (P < 0.0001).
“This study provides important insights into the design of medication management programs tailored to this population. Future studies should incorporate a control population to improve the interpretation of study results,” the authors concluded.
Researchers report an increase in breast cancer survivor’s use of chronic medication after cancer treatment.
- Cholesterol-Lowering Drugs May Prevent Breast Cancer Recurrence
- Idelalisib Increases Progression-Free Survival in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia
- Some Early Breast Cancer Patients Should Have Breast Conservation Instead of Mastectomy
- BBD Regimen Efficacious as First-line Therapy for Myeloma
- Trends in Behaviors, Medical Practice Indicate Mortality From Melanoma Will Decline
- Survivors Reporting Chronic Neuropathic Pain Struggle to Retain Jobs
- Timing of Chemotherapy Infusion Affects Inflammatory Response to Chemotherapy
- Postoperative Gemcitabine Plus Capecitabine: A New Standard of Care for Pancreatic Cancer
- Blood-Forming Stem Cell Transplants (Fact Sheet)
- Nut Consumption Inversely Associated With Lung Cancer Risk
- Targeting AR Mutations Promising in Metastatic Prostate Cancer
- GUCS 2017: Early Immunotherapy Discontinuation in mRCC
- Pembrolizumab Active Against Rare Melanoma, Extends Survival in Bladder Cancer
- Myalgia-arthralgia Syndrome Associated With Taxanes in Patients with Breast Cancer
- Women Treated for DCIS Have Slightly Lower Risk for All-Cause Mortality
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|